Increasing implementation of microfluidic technologies require smaller sample sizes while enabling more rapid diagnostic results and reducing the overall size of IVD instruments.

by: Carl Sims, Joseph Rotter, and Quan Liu

A study evaluated the workflow efficiency of a laboratory automation system, suggesting that fully automated and integrated nucleic acid testing systems can help to enhance blood testing laboratory logistics, human resource utilization, and screening turnaround times.

by: Gilles Delage, Louis Thibault, and Frank Strobl

Manufacturer pricing of cardiac POCT within the National Health Service as a means of overcoming adoption barriers and meeting reimbursement policy issues.

by: Francis FitzGibbon, David Huckle, and Brian J. Meenan

As innovations in point-of-care testing gain steam, the regulatory landscape becomes more complicated.

by: Interview by Richard Park

Lessons and results from the Public Consultation document.

by: Dirk Stynen, PhD

IT innovations are opening new pathways in clinical diagnostics and broadening how we measure and define success.

by: Michael Reitermann

In March, FDA’s Molecular and Clinical Genetics Panel held a meeting to discuss and make recommendations on scientific issues concerning direct-to-consumer (DTC) genetic tests that make medical claims.

by: Richard Park

Industry observers and Wall Street traders alike have taken a keen interest in Gen-Probe’s activities and investor announcements this quarter.

by: Maureen Kingsley

In April Seegene Inc. (Seoul) announced a partnership with Samsung Medical Center (Seoul) to codevelop molecular diagnostics for cancer. Seegene will bring to this collaboration its molecular diagnostic technology knowledge, and Samsung Medical Center will contribute its clinical and disease-pathology expertise. Samsung Medical Center will also provide the first test sites for the tests.

by: Maureen Kingsley